Fabhalta® is the official global commercial brand name, and Feiheda is its Chinese brand name developed by Novartis. It is an oral proximal complement factor B inhibitor. It targets complement factor B of the alternative complement pathway, blocks abnormal complement‑mediated…
Ocrevus® is the official global commercial brand name, and Luokeshi is its Chinese brand name developed by Roche. It is a humanized anti‑CD20 monoclonal antibody. It selectively depletes CD20‑positive B‑lymphocytes, inhibits pathological autoimmune inflammatory responses in the central nervous system,…
Stelara® is the official global commercial brand name, and Xidanuo is its Chinese brand name developed by Janssen. It is a fully‑human monoclonal antibody. It targets the p40 subunit of interleukin‑12 (IL‑12) and interleukin‑23 (IL‑23), blocks abnormal inflammatory signalling pathways,…
Ilumetri® is the official global commercial brand name, and Yiluqu is its Chinese brand name. It is a humanized IgG1κ monoclonal antibody targeting interleukin‑23 (IL‑23). It selectively binds to the p19 subunit of IL‑23, inhibits IL‑23-mediated inflammatory signaling, suppresses abnormal…
Sylvant® is the official global commercial brand name, and Sawenke is its Chinese brand name. It is a chimeric monoclonal antibody targeting interleukin-6 (IL-6). It specifically binds to human IL-6, blocks IL-6-mediated signal transduction, inhibits abnormal lymphocyte proliferation and inflammatory…
Enspryng® is the official global commercial brand name, and Anshiping is its Chinese brand name developed by Roche. It is a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. It selectively binds to IL-6 receptor, blocks IL-6 signal transduction, suppresses abnormal autoimmune…
Spevigo® is the commercial brand name of Spesolimab Injection, a humanized selective monoclonal antibody targeting IL‑36 receptor developed by Boehringer Ingelheim. It blocks the activation of IL‑36R and inhibits downstream inflammatory cascades to control flares of generalized pustular psoriasis. Main…
Skyrizi® is the commercial brand name of Risankizumab Injection, a fully human monoclonal antibody targeting IL‑23p19 developed by AbbVie. It selectively binds interleukin‑23 and blocks downstream inflammatory pathways to suppress excessive immune inflammation. Main IndicationsTreatment of moderately to severely active…
Tremfya® is the commercial brand name of Guselkumab Injection, a fully human monoclonal antibody against IL‑23p19 developed by Janssen. It specifically binds interleukin‑23 to interrupt the inflammatory cascade, alleviating immune-mediated inflammatory lesions. Main IndicationsTreatment of moderately to severely active Crohn’s…
Enbrel® is the commercial brand name of Etanercept Solution for Injection, a recombinant human tumor necrosis factor receptor fusion protein developed by Pfizer. It competitively binds to TNF-α and blocks its pro-inflammatory biological activity, thereby alleviating autoimmune inflammatory lesions. Main…